Conference Magazine - GoingPublic.de - Deutsches Eigenkapitalforum

Capital Seeking Companies
Profile
Founded in 2008
Number of employees 30
Equity (in EUR million) 3
Financing needs (in EUR million) 12
Positive result from 2014
Revenues in 2010 (in EUR million) 0.5
Revenues in 2011 (in EUR million) 1.2
Revenues in 2012 (e) (in EUR million) 2.5
Revenues in 2013 (e) (in EUR million) 3.0
Contact
Contact person Dr. Jörg Riesmeier
Phone +49-(0) 2 21-4 74 48-1 01
E-mail joerg.riesmeier@direvo.com
Website www.direvo.com
Address Nattermannallee 1
50829 Cologne
Germany
Business field
Direvo is a biotechnology company that focuses on the biomass
conversion industry. Direvo identifies bottlenecks and
weaknesses in current industrial processes in this sector
and develops and implements biology-based solutions
together with both large and small industrial partners.
Direvo’s products are newly-designed enzymes and microorganisms
of the highest quality that provide easy-toimplement,
cost-effective solutions. Direvo’s contribution
ensures that partners stay competitive and profitable while
Direvo enhances their ability to make the future cleaner,
greener and safer.
Strategic market position
At Direvo, we focus on the emerging biomass conversion
industry. We identify bottlenecks and weaknesses in
current industrial processes in this sector. We develop
Page 136 Deutsches Eigenkapitalforum 2012
Direvo Industrial
Biotechnology GmbH
Renewable energies
biology-based solutions and implement these for our partners
and customers, which include both large and small
industrial companies. Our BluZy product development
platform, which delivers innovative biology-based solutions
to improve the economics of the renewable fuels and livestock
feeding markets, has just been launched. It’s objective
is to get the most and best out of every bushel of corn.
Management
DIREVO is run by an international management team with
extensive experience in the biotech industries: Dr. Jörg
Riesmeier, CEO; Andreas Lischka, VP Finance & Administration;
Klaudija Milos, VP Industrial Solutions Business
Unit; Dr. Albrecht Läufer, VP Lignocellulose Business Unit
From left to right: Dr. Jörg Riesmeier, Klaudija Milos, Dr. Albrecht Läufer,
Andreas Lischka
Planned investment, shareholders / investors
DIREVO Industrial Biotechnology GmbH is financed by
venture capital and private investors. Current investors
include: TVM V Life Science Ventures GmbH & Co. KG,
Munich; NRW.Bank Venture Fonds GmbH & Co. KG, Düsseldorf;
Wölbern Equity Partner GmbH, Hamburg; SKB
Kapitalbeteiligungsgesellschaft Köln-Bonn mbH, Cologne;
Mulligan BioCapital, Hamburg; SMH Enzymes LLC, New
York; Danisco Venture A/S, Copenhagen and several
private investors.